Altre lingue ARS Pharmaceuticals, Inc.

Azioni

SPRY

US82835W1080

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 16/04/2024			Variaz. 5gg	Var. 1 gen.
9,18 ^USD	-0,65%		-1,61%	+67,52%

10/04	L'insider di Ars Pharmaceuticals ha venduto azioni per un valore di $927.735, secondo un recente deposito SEC	MT
03/04	ARS Pharmaceuticals presenta una risposta alla lettera di risposta completa della FDA per Neffy	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	10/04
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21/03
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	18/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day	08/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day	07/03
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024	06/03
North American Morning Briefing : Stock Futures -2-	06/03
ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	27/02
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26/02
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26/02
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study	26/02
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024	22/02
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter	21/02
ARS Pharmaceuticals' Repeat Dose Study Shows Epinephrine Nasal Spray as Good as Injection	20/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ARS Pharmaceuticals, Inc.

Azioni

SPRY

US82835W1080

Altre lingue

Filtri